Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT

User menu

Search

  • Advanced search
eNeuro
eNeuro

Advanced Search

 

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT
PreviousNext
Research ArticleResearch Article: Confirmation, Disorders of the Nervous System

Amyloid β-Peptide Effects on Glucose Regulation Are Dependent on Apolipoprotein E Genotype

Jin Hee Sung, Yang Ou and Steven W. Barger
eNeuro 26 April 2023, 10 (4) ENEURO.0376-22.2023; https://doi.org/10.1523/ENEURO.0376-22.2023
Jin Hee Sung
1Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yang Ou
1Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven W. Barger
1Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72205
2Department of Neurobiology and Developmental Sciences, University of Arkansas for Medical Sciences, Little Rock, AR 72205
3Geriatric Research, Education and Clinical Center, Central Arkansas Veterans Healthcare System, Little Rock, AR 72205
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The apolipoprotein E gene (APOE) confers the greatest genetic risk factor for Alzheimer’s disease (AD), wherein the ε4 allele confers an elevated risk compared with the ε3 allele. Biological mechanisms that differ across these alleles have been explored in mouse models wherein the murine Apoe gene has undergone targeted replacement with sequences encoding human ApoE3 or ApoE4 (ApoE-TR mice). Such models have indicated that the two variants of ApoE produce differential effects on energy metabolism, including metabolic syndrome. However, glucose regulation has not been compared in ApoE-TR mice with and without amyloid β-peptide (Aβ) accumulation. We crossed ApoE3-TR and ApoE4-TR mice with a transgenic line that accumulates human Aβ1-42. In male ApoE3-TR mice, introduction of Aβ caused aberrations in glucose tolerance and in membrane translocation of astrocytic glucose transporter 1 (GLUT1). Phosphorylation of Tau at AD-relevant sites was correlated with glucose intolerance. These effects appeared independent of insulin dysregulation and were not observed in females. In ApoE4-TR mice, the addition of Aβ had no significant effects because of a trend toward perturbation of the baseline values.

  • Alzheimer’s disease
  • amyloid β-peptide
  • apolipoprotein E
  • glucose
  • insulin
  • microtubule-associated protein Tau

Significance Statement

Metabolic changes may have a larger interaction with Alzheimer’s disease (AD) pathology and its consequences in individuals who do not carry an APOE ε4 allele. The fact that ApoE4 generally failed to exacerbate the effects of amyloid β (Aβ) on glucose further highlights the growing distinction between the glycemic effects of Aβ versus those of peripheral insulin resistance.

Introduction

Alzheimer’s disease (AD) is a chronic and irreversible brain disorder that involves memory loss and decline of cognitive ability. Risk for developing AD is elevated in a dose-dependent manner by the ε4 allele of the gene (APOE) for apolipoprotein E (ApoE), relative to the more common ε3 allele. A wealth of genetic, biochemical, and neuropathological evidence indicates that CNS accumulation of amyloid β-peptide (Aβ)—either as plaques or in a more diffuse, even soluble, form—is the precipitating etiologic event for AD. Accumulation of Aβ is higher in individuals with an APOE ε4 allele. This relationship has led to the hypothesis that APOE ε4 is associated with higher rates of AD because its protein product (ApoE4) promotes Aβ aggregation or retention in the brain. However, other mechanisms are possible, and considerable evidence indicates that the protein product of the APOE ε4 allele (ApoE4) enters the cell nucleus and binds specific gene enhancer elements (Parcon et al., 2018; Lima et al., 2020).

One of the earliest events in AD pathogenesis after CNS accumulation of Aβ is a decline in cerebral metabolism of glucose (CMRglc; Jack et al., 2000). The decline in CMRglc is highly correlated with cognitive impairment, and it has impressive specificity as a predictor of progression from mild cognitive impairment (MCI) to frank dementia (Smailagic et al., 2018; Shen et al., 2019) or from normal cognition to MCI (Reiman et al., 1998; de Leon et al., 2001; Mosconi et al., 2008). We recently determined that CMRglc contributes to somatic glucose tolerance, as a transgenic mouse line that accumulates Aβ in the CNS has both reduced CMRglc and impaired glucose tolerance. This appears to result from a decrease in the fraction of glucose transporter 1 (GLUT1) subcellularly localized to the plasma membrane of astrocytes (or other CNS parenchymal cells; Hendrix et al., 2021). This effect on the 45-kDa form of GLUT1 was also observed in human cerebrum and was the only significant alteration in glucose transporters we identified; reduction of GLUT3, the only CNS transporter that is unique to neurons, does not suppress CMRglc (Stuart et al., 2011).

Persons homozygous for the ε4 allele of APOE show an age-related drop in CMRglc in the absence of—or, implicitly, before—cognitive impairment (Small et al., 1995; Reiman et al., 1996, 1998). Female mice carrying targeted replacement (TR) of the murine Apoe gene with sequences encoding human ApoE4 show impaired glucose tolerance compared with ApoE3-TR mice (Koren-Iton et al., 2020), but this difference may disappear when compounded by the pathologies associated with diet-induced obesity or Aβ accumulation (Christensen and Pike, 2019; Koren-Iton et al., 2020). The latter manipulation was performed through transgenesis for the full amyloid precursor protein (APP), which has marked effects on peripheral glucose regulation (Needham et al., 2008; Tu et al., 2012; Botteri et al., 2018; Kulas et al., 2019).

Here, we sought to determine the impact of human ApoE4 on glucose regulation in a mouse model that suffers CNS Aβ accumulation without an APP transgene. Unlike prior studies, we directly compared ApoE-TR mice with and without human Aβ expression. To gain greater understanding of the point(s) in brain glucose metabolism impacted by APOE genotype, we performed glucose tolerance tests (GTTs) and insulin tolerance tests, and we looked for relationships between these parameters and markers of AD-related pathology, including reduced membrane trafficking of GLUT1, Tau hyperphosphorylation, and interleukin-1β (IL-1β) expression. Glucose uptake rates in primary astrocytes derived from ApoE-TR mice was also assayed to scrutinize events happening at the cell-autonomous level.

Materials and Methods

ApoE-targeted replacement mice

Mice homozygous for ApoE3-TR or ApoE4-TR loci (Sullivan et al., 1997) were assessed alongside ApoE-TR mice from the same breeding colony that were also carrying an Aβ1-42 transgene (Aβ-Tg) hemizygously, the latter generated by crossing the ApoE-TR lines with the BRI-Aβ42 line. These “Aβ-Tg” mice achieve high expression and release of human Aβ1–42 through transgenesis with a fusion protein construct that is transported to the plasmalemma, where the Aβ portion is released by furin protease (McGowan et al., 2005); this model thus avoids APP overexpression, which could otherwise confound glucose regulation (Kulas et al., 2019). Mice were maintained on a 12/12 h light/dark cycle (ZT0 = 6 A.M.) at 23°C with free access to food and water. Both males and females were used. All animal experiments were conducted according to the Institutional Animal Care and Use Committee of the Central Arkansas Veterans Healthcare System (CAVHS), which is certified by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). Mice were anesthetized in a CO2 chamber. Left brains were collected, snap-frozen in liquid N2, and stored at −80°C for biochemical assays.

Genotyping

Blood samples from tail nicks were collected on Whatman FTA card (Millipore Sigma). Total genomic DNA from blood was isolated using REDExtract-N-Amp Blood PCR kit (Millipore Sigma) following the manufacturer’s instructions. PCR was performed on the extracted DNA with the following primers: BRI-Aβ42 forward: 5'-AAG GCT GGA ACC TAT TTG CC- 3′, reverse: 5'-TAG TGG ATC CCT ACG CTA TG-3′; APOE-TR forward: 5'-GGT AGC TAG CCT GGA CGG-3′, reverse: 5'-GCT AGA ACC AGC AGA GAC CC-3′; Apoe-WT forward: 5'-GTC TCG GCT CTG AAC TAC TAT-3′, reverse: 5'-GCA AGA GGT GAT GGT ACT CG-3′.

GTT and ITT

Glucose tolerance test (GTT) was performed at seven weeks or 12 months of age. Mice fasted for 6 h, and then D-(+)-glucose (2 g/kg) was injected intraperitoneally. Concentration of glucose in tail-vein blood ([Glc]b] was assayed before injection and at 15, 30, 60, and 120 min after injection using an AlphaTRAK Glucose Meter (Zoetis Inc). Area under the curve (AUC) was calculated as total AUC (tAUC), which compares absolute values of [Glc]b. Insulin tolerance test (ITT) performed to assess insulin sensitivity at seven weeks of age. Nonfasted mice were transferred to individual cages injected with 1 U/kg insulin (Humulin R, Lily) intraperitoneally. Blood glucose was measured by the same method as for GTT. Because ITT produces a downward deflection from baseline, integration of these values was performed as area over the curve (AOC), measured from the initial [Glc]b.

Western blot analysis and Wes immunoassay

Harvested brain tissue was stored at −80°C and then chilled further in liquid N2 before being pulverized with a liquid N2-chilled mortar and pestle. For conventional Western blot analysis, pulverized tissue was combined with RIPA buffer (50 mm Tris-HCl, 150 mm NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mm Na3VO4, 1 mm NaF) containing 5 mg/ml protease inhibitors (Pierce Mini Tablets, EDTA-free), pH 7.5) and sonicated on ice. The lysates were quantified for protein with the Pierce BCA protein assay kit (Thermo Fisher Scientific). Total protein (30 μg per lane) was separated by SDS-PAGE using 4–15% Tris‐glycine gels (Bio‐Rad Laboratories) and transferred to PVDF membrane (Millipore Sigma). The blots were blocked with SuperBlock Blocking Buffer (Thermo Fisher Scientific) for 1 h at room temperature and then incubated with primary antibody overnight at 4°C: AT8, detecting phosphorylated Tau (Thermo Fisher Scientific, MN1020, 1:250), a phospho-independent anti-Tau antibody (Cell Signaling, #46687, 1:1000), or an anti-IL1β antibody (ABclonal, #A16228, 1:1000). The membranes were washed in Tris-buffered saline containing 0.1% Tween 20 (TBST) and then exposed to secondary antibody: anti-rabbit and anti-mouse HRP conjugated (Thermo Fisher Scientific). After washing in TBST, the membranes were reacted with enhanced chemiluminescent substrate (Thermo Fisher Scientific). Protein bands were visualized by exposure to x-ray film and quantification performed with ImageJ.

For analysis of GLUT1, membrane fractionation was performed with a Minute Plasma Membrane Protein Isolation and Cell Fractionation kit (Invent Biotechnologies), which allows separation of tissue homogenates into plasma membrane (PM), cytosolic, and organellar fractions. As previously described (Hendrix et al., 2021), these fractions were analyzed on a SimpleWes capillary electrophoresis device (Protein Simple), which provides requisite separation of the molecular-weight moieties and quantitation. The value obtained for the 45-kDa GLUT1 in each fraction was multiplied by the dilution factor of each, then the PM value was divided by the total of all fractions.

ELISA

After a 6-h fast, tail-vein blood was collected at 0 and 30 min relative to an intraperitoneal injection of 2 g/kg glucose (as per GTT). Blood samples were allowed to coagulate and then centrifuged at 17,000 × g for 15 min at 4°C. Serum samples were stored at −80°C. Insulin ELISA was performed using an Ultra-Sensitive Mouse Insulin ELISA kit (Crystal Chem) according to manufacturer’s instructions.

For cerebral Aβ ELISA, pulverized brain samples were weighed before extraction. Brain tissues were homogenized in 15 times their volume of ice-cold extraction buffer [Tris-buffered saline (TBS) containing 1 mm Na3VO4, 1 mm NaF, and 5 mg/ml protease inhibitors (Pierce Mini Tablets, EDTA-free)] and centrifuged at 100,000 × g for 60 min at 4°C. The supernatants were stored for determination of water-soluble Aβ. The pellets were washed in TBS and suspended in 50 μl extraction buffer with 1% Triton X-100 (“Deterg.” in Table 3). The suspensions were mixed using a gentle rotator for 30 min 4°C and centrifuged at 100,000 × g for 60 min at 4°C. These supernatants were stored for determination of detergent-soluble Aβ. The pellets were washed in TBS and resuspended in extraction buffer containing 70% formic acid (“F.A.” in Table 3). The samples were mixed on a rotator for 2 h at room temperature. After mixing, the suspensions were centrifuged at 100,000 × g for 60 min at 4°C. These supernatants were stored for acid-soluble Aβ analysis. All supernatants were stored at −80°C before ELISA. Aβ ELISA was performed using a human amyloid β (aa1-42) immunoassay Quantikine ELISA kit (R&D Systems).

Primary culture of astrocytes

Astrocytes were isolated from postnatal-day-1 to -3 Sprague Dawley rat pups or mouse pups of wild-type, ApoE3-TR, and ApoE4-TR genotypes and mixed sexes. Pups were anesthetized by hypothermia, sanitized with 70% ethanol, and transferred into HEPES-buffered HBSS (Millipore Sigma). Brains were removed and the cerebral hemispheres removed from midbrain and brainstem. Meninges and olfactory bulbs were removed. Cerebral hemispheres were diced with a scalpel blade and incubated in 0.1 mg/ml trypsin (Thermo Fisher Scientific) in HBSS for 8 min at room temperature. The tissues were rinsed with HBSS and exposed to 1.5 mg/ml trypsin inhibitor (Thermo Fisher Scientific) for 10 min at room temperature. After rinsing the tissue with HBSS, the tissue was triturated and plated in tissue culture flasks with minimal essential medium (Earle’s salts; MEM) containing 10% fetal bovine serum (FBS). After 10–14 d, the loosely attached microglia were dislodged by striking the flask abruptly and washing with phosphate-buffered saline (PBS). The remaining astrocytes were then trypsinized for subculturing. For subcellular fractionation, cells were plated in 150-mm plates (three per data point). Once confluent, the culture medium was replaced with DMEM containing 0.5% FBS with 5 or 0.2 mm glucose for 24 h.

Glucose uptake assay

Aβ1-42 (rPeptide) was prepared by first dissolving in hexafluoroisopropanol (HFIP) at 1 mm for 3–4 h to remove any preexisting fibrils. The HFIP was removed by evaporation, and the peptide was dissolved in anhydrous dimethyl sulfoxide at 2 mm, then diluted to 150 μm in ice-cold PBS. The solution was incubated at 4°C for 24 h to allow for the formation of oligomers.

Subcultured primary astrocytes were seeded in 24-well plates and grown to confluency. Once confluent the growth medium was replaced with MEM containing 0.5% FBS with 2.5 μm Aβ1-42 or vehicle for 4 h before harvest. The medium was then replaced with DMEM lacking glucose, containing 10 μCi/ml [3H]2-deoxyglucose and 1 μCi/ml [14C]sucrose. After 30 min, the medium was removed and stored for scintillation counting. The cells were washed twice with ice-cold DMEM containing 25 mm glucose then lysed via a freeze-thaw cycle in 10 mm Tris-HCl (pH 7.2) containing 0.2% sodium dodecyl sulfate. One aliquot was subjected to scintillation counting and another to protein determination by BCA reaction. The 14C cpm/ml in medium was used to determine the volume of extraneous medium contributing to each cell lysate, and 3H cpm corresponding to this volume were subtracted from the total in the lysate. Finally, the remaining 3H cpm were normalized to the protein content in the well.

Statistical analysis

Datasets including both genotypes, with and without the Aβ transgene, were assessed by two-way ANOVA followed by the indicated post hoc test. Pearson’s correlation coefficient was used to analyze correlations. Values of p < 0.05 were considered statistically significant.

Results

Aβ significantly impairs glucose tolerance in male ApoE3-TR mice

We previously reported that accumulation of Aβ1-42 in the CNS of mice is sufficient to impair peripherally measured glucose tolerance without disruption of insulin dynamics. ApoE3-TR and ApoE4-TR mice were crossed with Aβ-Tg mice, and these were compared with their Aβ-free counterparts regarding glucose and insulin regulation. Male ApoE3-TR/Aβ-Tg mice tested at 12 months of age exhibited impairments in a glucose tolerance test (GTT) compared with ApoE3-TR mice without an Aβ transgene (Fig. 1A). ApoE4-TR mice trended toward an impairment, and this prevented the apparent elevation by Aβ from reaching significance. As we had observed earlier in mice with a wild-type Apoe locus (Hendrix et al., 2021), glucose tolerance in females expressing either of the human ApoE variants was unaffected by Aβ accumulation (Fig. 1B). ApoE4-TR females showed a small trend toward impairment compared with ApoE3-TR females, regardless of Aβ expression, but this did not reach significance. Body weights did not differ between the genotypes in either sex (Table 1). To test the effects of age, additional GTTs were performed on seven-week-old males. Compared with older males, the total area under the curve (tAUC) during the 2-h GTT was 29% lower in the younger ApoE3-TR and 4TR mice (without the Aβ transgene). Therefore, the results are presented as the percentage of ApoE3-TR values in each respective age group so that relative differences between the genotypes could be more readily compared across the ages (Fig. 1C). The relationships between ApoE variant, Aβ expression, and GTT followed essentially the same pattern in each age group, though Aβ trended toward a greater effect regardless of ApoE variant. The younger male cohort was used for the data presented henceforth.

View this table:
  • View inline
  • View popup
Table 1

Body weights

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Aβ impairs glucose tolerance in male mice expressing ApoE3. Aβ-Tg mice mice were crossed with mice which had undergone targeted replacement (TR) of the endogenous Apoe gene with sequences producing human ApoE3 or ApoE4. They were compared with littermates which did not inherit the Aβ-Tg. GTT was performed on 12-month-old male mice (A) or female mice (B); p < 0.02 ApoE3-TR versus ApoE3-TR/Aβ-Tg, males only (two-way ANOVA and Bonferroni post hoc). C, AUC was calculated from GTT values for seven-week-old and 12-month-old male mice. Results are shown relative to the mean values from ApoE3-TR mice at each age; two-way ANOVA indicated no interaction, no main effect of ApoE variant, and a main effect of Aβ (p < 0.01, each of the ages); *p < 0.03 versus ApoE3-TR, **p < 0.01 versus ApoE3-TR by Bonferroni post hoc. D, ITT on males reflected as area over the curve (AOC). Values represent mean ± SEM (N = 7–10). In all figures, blue represents ApoE3-TR and red represents ApoE4-TR; the addition of Aβ-Tg to these ApoE genotypes is represented by cross hatching (bar graphs) or dashed line (line graphs).

As seen in mice with a wild-type Apoe locus (Hendrix et al., 2021), the impaired glucose tolerance in ApoE3-TR males was not associated with insulin resistance. ITT showed no differences between any of the genotypes, as reflected in area over the curve in Figure 1D. Serum levels of insulin were measured after fasting (t(30)) and 30 min after intraperitoneal glucose administration (t(30)), and no significant differences between the genotypes were detected (Table 2). An effect of Aβ was noted in male ApoE4-TR mice in the form of a basal blood glucose concentration ([Glc]b) that remained elevated in the fasted state (Fig. 2A,B). In the nonfasted state, there was no difference in basal [Glc]b among the groups. None of these effects appeared to be mediated by substantive differences in the accumulation of Aβ between ApoE3-TR and ApoE4-TR mice (Table 3).

View this table:
  • View inline
  • View popup
Table 2

Serum insulin levels

View this table:
  • View inline
  • View popup
Table 3

Cerebral aβ levels

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Aβ combines with ApoE4 expression to elevate basal [Glc]b. Basal [Glc]b was measured in males of ApoE3-TR, ApoE3-TR/Aβ, ApoE4-TR, and ApoE4-TR/Aβ genotypes. The mice had either been fasted 5 h (A) or not (B). Values represent mean ± SEM (N = 7–10). In the fasted condition, two-way ANOVA indicated no interaction, no main effect of Aβ, and a main effect of ApoE variant (p < 0.05); *p < 0.03 by Bonferroni post hoc.

Aβ significantly impairs GLUT1 membrane localization in ApoE3-TR mice

The impairments in GTT in male Aβ-Tg mice were previously associated with deficient trafficking of GLUT1 in brain parenchymal cells. Specifically, the proportion of the 45-kDa form of GLUT1 in cortical plasma membrane fractions was lower in these mice, as it was in AD (Hendrix et al., 2021). We examined this property in ApoE-TR males. The results revealed a pattern reciprocal to that of GTT: ApoE3-TR/Aβ-Tg mice exhibited a plasma membrane (PM) fraction of 45-kDa GLUT1 that was significantly lower than that in ApoE3-TR mice; ApoE4-TR mice trended toward a lower value, which obviated a significant difference between these and their ApoE4-TR/Aβ-Tg counterparts (Fig. 3). Total levels of GLUT1 in the four groups did not differ (data not shown).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Aβ impairs plasmalemmal localization of parenchymal GLUT1 in cerebral cortex of ApoE3-TR mice. Cerebral hemispheres from ApoE3-TR, ApoE3-TR/Aβ, ApoE4-TR, and ApoE4-TR/Aβ genotypes were homogenized and fractionated to isolate plasma membrane (PM). Steady-state levels of the 45-kDa isoform of GLUT1 were determined in this fraction and the remainder of cellular components using SimpleWes capillary electrophoresis. A, Virtual bands created by the SimpleWes software. B, Quantification of mean PM fraction ± SEM (N = 6); two-way ANOVA indicated no interaction, no main effect of ApoE variant, and a main effect of Aβ (p < 0.002); *p < 0.02 by Bonferroni post hoc, n.s.: p = 0.08.

Both Aβ and ApoE4 are required to alter GLUT1 and glucose uptake in cultured astrocytes

We also assayed the PM fraction of 45-kDa GLUT1 in astrocytes cultured from ApoE3-TR and ApoE4-TR mice. Basal PM fraction of GLUT1 was not significantly different between ApoE3-TR and ApoE4-expressing astrocytes under normal culture conditions. As seen in prior studies with wild-type adipocytes and myocytes, reduction of glucose concentration in the culture medium enhanced the amount of GLUT1 in the PM fraction in astrocytes from ApoE3-TR mice (Fig. 4A). In contrast, the PM fraction of GLUT1 was deflected downward, resulting in a significant difference between the genotypes.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Both Aβ and ApoE4 are required to impair glucose transport in cultured astrocytes. Primary astrocyte cultures were prepared from postnatal mice of ApoE3 or ApoE4 mice. A, Cells were cultured in DMEM containing 5 or 0.2 mm Glc. Homogenates were fractionated to isolate plasma membrane (PM), and levels of the 45-kDa GLUT1 were determined by SimpleWes. Quantification of mean plasmalemma fraction ± SEM (N = 4); two-way ANOVA indicated no main effect of [Glc], a main effect of ApoE variant (p < 0.02), and a significant interaction (p < 0.03); *p < 0.01 by Bonferroni post hoc. B, Cultures were treated with 2.5 μm aggregated Aβ1-42. After 20 h, a 30-min uptake of [3H]2-deoxyglucose ([3H]2DG) was measured, corrected by inclusion of [14C]sucrose and normalized to protein quantity. Values represent mean ± SEM (N = 4); two-way ANOVA indicated a main effect of ApoE variant (p < 0.003), a main effect of Aβ (p < 0.03), and a significant interaction (p < 0.02); *p = 0.002 by Bonferroni post hoc.

To test for effects of ApoE variant on glucose uptake, we assayed acute accumulation of [3H]2-deoxyglucose (2DG) in cultured astrocytes. Some cultures were exposed to 2.5 μm Aβ1-42 for 8 h before assay. (This time period was sufficient to down-regulate GLUT1 PM fraction in wild-type astrocytes.) Within a 30-min incubation with [3H]2DG, ApoE3-TR and ApoE4-TR astrocytes had taken up essentially equal amounts compared with ApoE4-TR astrocytes (Fig. 4B). Exposure to Aβ reduced the uptake of 2DG in ApoE4-TR cells, but the rate in ApoE3-TR cells was not significantly impacted by Aβ.

ApoE4 expression elevates expression of pro-IL-1β without elevating maturation

Activation of inflammatory sequelae is well established in AD, and variant-specific effects of ApoE on these molecules and pathways have been reported (Vitek et al., 2009; Kloske and Wilcock, 2020). Interleukin-1β (IL-1β) is a well-documented component of the neuroinflammatory changes seen in AD and has mechanistic connections to aspects of AD pathology. In addition, we previously found that proinflammatory cytokines can impair translocation of astrocytic GLUT1 to the plasma membrane (Hendrix et al., 2021). We measured IL-1β levels in the brains of ApoE-TR males, with or without the Aβ transgene. Because maturation and release of IL-1β depends on activation of the inflammasome, we prefer to assay this cytokine by Western blotting rather than ELISA, as the former allows assessment of mobility to distinguish pro-IL-1β (35 kDa) from mature IL-1β (17 kDa). Western blot analysis of cerebral cortical tissue detected an elevation of pro-IL-1β that was dependent on ApoE4 expression and not Aβ (Fig. 5A,B). However, mature IL-1β was unaltered by either (Fig. 5A,C). The latter finding is consistent with a similar recalcitrance of interleukin-1-converting enzyme (ICE; caspase 1; data not shown).

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

ApoE4 expression is associated with higher levels of pro-IL-1β but not mature IL-1β. Cerebral hemispheres from ApoE3-TR, ApoE3-TR/Aβ, ApoE4-TR, and ApoE4-TR/Aβ genotypes were homogenized and analyzed by Western blotting for IL-1β (A); β-actin was quantified as a loading control. The 35-kDa proIL-1β (B) and 17-kDa mature IL-1β (C) were quantified separately (mean ± SEM; N = 6). A two-way ANOVA of proIL-1β indicated no interaction, no main effect of Aβ, and a main effect of ApoE variant (p < 0.003); *p = 0.03 by Bonferroni post hoc.

Tau hyperphosphorylation mirrors GTT perturbation

To determine whether markers related to neurodegeneration were altered by ApoE variant we evaluated the phosphorylation state of Tau in cerebral tissue from ApoE-TR males. Western blottings for pathologic Tau were performed with the AT8 antibody, which detects Tau phosphorylated at amino acids Ser202 and Thr205 (pTau); these sites are phosphorylated in neurofibrillary tangles found in AD and other tauopathies (Biernat et al., 1992). pTau immunoreactivity was normalized to results obtained with a phosphorylation-independent Tau antibody. GTT results were tabulated as area under the curve (AUC) to provide an integrated assessment of glucose derangement. Both parameters showed a similar step-wise increase from ApoE3-TR to ApoE4-TR to ApoE3-TR/Aβ-Tg (Fig. 6). Moreover, when the correlation was calculated between GTT AUC and pTau/Tau values for each animal, significance was observed for the overall cohort, all ApoE3-TR mice, and all mice lacking Aβ (Table 4); analysis of all ApoE4-TR and all Aβ-Tg mice showed no significance.

View this table:
  • View inline
  • View popup
Table 4

GTT versus AT8/Tau correlation

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

Tau pathology approximates glucose perturbation in Aβ-Tg x ApoE-TR mice. ApoE3-TR and ApoE4-TR mice were cross-bred to Aβ-Tg mice to produce males (7 weeks of age) that were homozygous for the ApoE allele and hemizygous for the Aβ transgene. A, Mice were assessed in a 2-h glucose tolerance (GTT) assay. B, Total AUC (mean ± SEM) for the GTT is plotted for each genotype; two-way ANOVA indicated no interaction, no main effect of ApoE variant, and a main effect of Aβ (p < 0.002); **p < 0.01 by Bonferroni post hoc. C, Cerebral cortex homogenates were subjected to Western blot analysis with an antibody to phosphorylated Tau (pTau; AT8 antibody) or a phospho-independent Tau antibody. D, Quantification of pTau/Tau ratio. Values are mean ± SEM; two-way ANOVA indicated no interaction, no main effect of ApoE variant, and a main effect of Aβ (p < 0.03); *p ≤ 0.02 by Bonferroni post hoc.

Discussion

We previously reported that accumulation of Aβ1-42 in the CNS of mice is sufficient to impair glucose tolerance without disruption of the production of or sensitivity to insulin. In fact, as the utilization of glucose in the CNS is largely insulin independent, impairment of glucose tolerance in the absence of insulin resistance may be a relatively specific marker for reduced CMRglc. We evaluated these parameters in mice expressing human ApoE3 and ApoE4 because of the impact of APOE genotype on rates of AD. We expected that ApoE4 would exacerbate the physiological effects of Aβ accumulation in the CNS. To effect the latter, we used an Aβ transgene that introduces Aβ1-42 into the brain interstitial fluid without an APP transgene. This was deemed an important departure from prior studies because of documented effects of APP on insulin and glucose regulation. Surprisingly, perturbations of glucose tolerance did not show significant cooperative effects of Aβ and ApoE4. Instead, ApoE4 itself tended to shift values in the direction of pathophysiology. In this way, the phenotype observed in ApoE3-expressing mice showed a greater dependence on Aβ.

The results reported here are compatible with evidence that ApoE4 impacts glucose utilization independently of AD pathogenesis (e.g., in young adults; Small et al., 1995; Reiman et al., 1996, 1998). The mice used in this study were relatively young, particularly as regards plaque development in this model, which typically becomes detectable at ∼12 months of age (McGowan et al., 2005). ELISA measurement of Aβ1-42 did not detect significant differences in the seven-week-old ApoE3-TR versus ApoE4-TR mice. If ApoE4 significantly exacerbated Aβ accumulation in this model system, it might be expected that the combination of an Aβ transgene with ApoE4 expression would create additive or perhaps even synergistic effects, but this was not observed, even in mice that were 12 months old. A combined effect of ApoE4 and Aβ was apparent only in basal [Glc]b of fasted mice. Thus, our findings suggest that ApoE4 could have detrimental effects by means other than worsening Aβ accumulation.

A few studies performed in mice combining human ApoE variants and Aβ accumulation have reported glucose dynamics, but none has directly compared ApoE-TR mice with and without the genetic manipulation of Aβ. In addition, prior studies attempted to model AD by overexpressing mutated APP. We and others have noted dramatic effects of APP on insulin and glucose regulation (Needham et al., 2008; Tu et al., 2012; Botteri et al., 2018; Kulas et al., 2019); therefore, we prefer a model of Aβ accumulation that does not depend on overexpression of APP. Pike and colleagues have made considerable study of a model (“EFAD”) wherein ApoE-TR mice are crossed with the 5xFAD line. EFAD mice responded to an obesogenic high-fat, high-sucrose (“Western”) diet in a manner reminiscent of the response we observed to Aβ: glucose tolerance was impaired by the diet-induced obesity in ApoE3-expressing mice but not in ApoE4-expressing mice. However, this relationship was shown in females (Christensen and Pike, 2019) but not males (Moser and Pike, 2017), opposite to the sex-dependency of the effects we observed. It is not clear what an increased vulnerability of females means in an animal model that does not experience menopause. While female humans develop AD at a higher rate than males, this is an entirely postmenopausal phenomenon (Seshadri et al., 1997; Riedel et al., 2016).

Several studies have evaluated glucose tolerance in ApoE-TR mice without any expression of human Aβ. Those have generally found no difference between the ApoE variants in GTT assays unless the mice were fed obesogenic diets (Arbones-Mainar et al., 2010; Jones et al., 2019; Mattar et al., 2022; Fleeman et al., 2023). Whereas female C57BL/6 mice with endogenous murine Apoe are generally refractory to obesogenic diets (Pettersson et al., 2012), expression of ApoE4 (but not ApoE3) seems to render them vulnerable to glucose intolerance (Jones et al., 2019). A study that exclusively used female mice found that, similar to the EFAD results described above, glucose tolerance was impaired by an obesogenic diet in ApoE3-expressing mice but not in ApoE4-expressing mice (Koren-Iton et al., 2020), whereas ApoE genotype failed to affect the response to an obesogenic diet in males (Arbones-Mainar et al., 2010). One study used mass spectrometry to assess plasma ApoE3 and ApoE4 levels in heterozygous human subjects, finding that [Glc]b was inversely related to the levels of ApoE3 but not correlated with ApoE4 levels (Edlund et al., 2021). Our findings are consistent with a report of mild effects of APOE ε4 on GTT in human subjects (Viitanen et al., 2001).

We did not find an effect of ApoE variant on insulin resistance, consistent with results in humans (Meigs et al., 2000; Ragogna et al., 2012). Accumulating evidence suggests that metabolic disorders make a larger contribution to all-cause dementia in APOE ε4 noncarriers than in APOE ε4 carriers. For instance, APOE ε4 homozygotes with AD are much less likely to have hyperinsulinemia than AD patients with other genotypes (Craft et al., 1998). And ketogenic supplements, which provide a fuel source alternative to glucose, provide greater benefits to cerebral blood flow and cognition in APOE ε4 noncarriers (Reger et al., 2004; Henderson et al., 2009; Torosyan et al., 2018). The cognitive benefits of intranasal insulin are similarly exaggerated in APOE ε4 noncarriers (Reger et al., 2006). Thus, the cases of all-cause dementia among APOE ε4 noncarriers may include a greater number of vascular dementia, whereas APOE ε4 is associated with bona fide “pure” AD. Studies in which AD diagnosis is limited to neuropathologically confirmed cases have consistently found no association with type-2 diabetes or metabolic syndrome (Heyman et al., 1984; Hassing et al., 2002; Peila et al., 2002; Thambisetty et al., 2013; Abner et al., 2016; Groeneveld et al., 2019; Sadrolashrafi et al., 2021). Likewise, we find disparate effects of type-2 diabetes and AD on cerebral glucose transporters (our unpublished observations).

One curious finding is that basal [Glc]b seemed to be modulated in a manner distinct from the conditions which impaired glucose dynamics, i.e., GTT. The latter showed a significant effect only when Aβ expressers and controls were compared in the ApoE3 background. However, this scenario did not affect basal fasted [Glc]b, which was altered only by the combination of ApoE4 and Aβ accumulation. Multiple mechanisms of action have been attributed to ApoE, some of which involve lipid transport or other events dependent on interaction of ApoE with its receptors. Distinct from these actions, ApoE4 can translocate to the cellular nucleus and act as a transcriptional repressor of a cis element termed coordinated lysosomal expression and regulation (CLEAR; Parcon et al., 2018; Lima et al., 2020). This element is otherwise bound by the transcriptional inducer TFEB to elevate expression of several genes involved in autophagy and other lysosomal processes. Thus, APOE ε4 may elevate the accumulation of Aβ and the risk for AD by suppressing proteostasis generally (Raha et al., 2021). The maximal GTT values reached in Aβ-Tg mice were practically identical in mice expressing ApoE3 or ApoE4. This is reminiscent of the similar binding affinities that the two variants have for lipoprotein receptors (Weisgraber et al., 1982). (ApoE2, by contrast, exhibits a much weaker interaction with LDLR and related receptors.) It is tempting to speculate that the association of ApoE variant with glucose tolerance —essentially equivalent GTT results across the two variants —is a product of receptor binding, whereas the modality in which a substantial ApoE4-dependent effect was observed —ApoE4’s elevation of basal [Glc]b in Aβ-expressing mice —is associated with a bioactivity in which a biochemical difference occurs, viz. CLEAR DNA binding. Failures in proteostasis appear to play an important role in the establishment of hyperglycemia and its underlying pathophysiology (Podolsky et al., 1972; Jung et al., 2008; Ozcan et al., 2009; Bachar-Wikstrom et al., 2013).

Human studies have consistently documented lower CMRglc in subjects possessing one or more APOE ε4 gene, even at early ages (Small et al., 1995; Reiman et al., 1996, 1998). An age-dependent reduction in glucose transport into the CNS has been reported in the ApoE-TR lines used here (Alata et al., 2015; Fang et al., 2021), though this was reported to occur at ages (8–12 months) far beyond most of the mice we examined. Surprisingly, another ApoE4-expressing model exhibits elevated CMRglc as it progresses into advanced ages (Kotredes et al., 2021). ApoE4 is associated with structural and functional deficits in the cerebrovasculature (Zlokovic, 2013; Tai et al., 2016), and it is possible that this contributes to the impact of APOE genotype on CMRglc.

Effects of vascular conditions, including hyperglycemia, on CMRglc typically involve downregulation of endothelial GLUT1 levels. Consistent with Alata and colleagues (Alata et al., 2015) and Wu and colleagues (Wu et al., 2018), we found no significant difference in total levels of GLUT1 (or other transporters) in ApoE4-TR mice. However, Aβ expression interfered with normal translocation of GLUT1 to the plasma membrane, as it does in mice with wild-type murine Apoe (Hendrix et al., 2021). This is correlated with reduced CMRglc values, and we hypothesize that the insulin-independent glucose intolerance effected by Aβ represents a surrogate marker of the glucose which is not used in the CNS, due primarily to dysfunctional GLUT1. This hypothesis is supported by GTT results after conditional knock-down of GLUT1 in the astrocytes of mice (our unpublished observations). It was surprising to see that cultured astrocytes were not affected in a manner predicted by in vivo results. Specifically, acute treatment of ApoE3-TR astrocytes with Aβ1-42 did not alter [3H]2DG as might be expected from the results with GTT and the PM fraction of 45-kDa GLUT1 in vivo. Instead, it was the ApoE4-TR astrocytes that exhibited diminished glucose transport in the presence of Aβ. Several differences between in vivo and in vitro conditions may explain this discrepancy, including the acute nature of the Aβ treatment in vitro and the cell-type complexity of the intact cerebrum.

IL-1β is well documented as a component of neuroinflammation in AD. Previously, we found that application of inflammatory cytokines to cultured astrocytes could create the deficit in GLUT1 plasma-membrane trafficking seen in response to Aβ (Hendrix et al., 2021). Here, we found that pro-IL-1β was elevated as a function of ApoE4 expression but not possession of the Aβ transgene. Perhaps more importantly, mature IL-1β was not affected by either ApoE status or Aβ expression. One reasonable interpretation is that ApoE4 elevated transcription of the Il1a gene relative to ApoE3 but did not elevate activity of the inflammasome, which is responsible for proteolytic processing of pro-IL-1β (Martinon et al., 2002). Consistent with the latter, the effects of ApoE4 on inflammation have been reported to be independent of the inflammasome (Igel et al., 2021), and we detected no differences in the levels of caspase 1/interleukin-1-converting enzyme in ApoE3-TR versus ApoE4-TR mice (data not shown).

The effects of ApoE variant on Tau hyperphosphorylation mirrored those on GTT. While overall Tau levels in cerebrospinal fluid have been associated with the APOE ε4 genotype (Blomberg et al., 1996; Galasko et al., 1998; Tapiola et al., 1998), there is less evidence for a robust effect of ApoE variant on neurofibrillary pathology in the parenchyma (Heinonen et al., 1995; Ohm et al., 1995; Zubenko et al., 1994). Tau pathology has been correlated with aberrations in brain glucose transporters (Liu et al., 2008), and decline of CMRglc is spatially correlated with higher Tau pathology detected by positon emission tomography (Ossenkoppele et al., 2016; Sun et al., 2020; Park et al., 2021), especially in the context of amyloid accumulation (Adams et al., 2019). In light of the association between impairments in GTT and CMRglc, our results support the idea that restricted glucose availability promotes Tau pathology, as suggested by reductionist experiments with cultured neurons (Cheng and Mattson, 1992; Lee et al., 2013).

In conclusion, we have, for the first time, compared glucose regulation in ApoE3-expressing and ApoE-expressing mice as a function of Aβ1–42 accumulation. We find that Aβ impairs glucose transport and tolerance in mice expressing human ApoE3 but makes less, if any, impact on these parameters in the presence of ApoE4. Thus, it is possible that Aβ accumulation is less important for development of glucose perturbation in APOE ε4 carriers, and—to the extent that Tau pathology mirrored these relationships—it may be less important to dementing neuropathology. It is also notable that metabolic interventions such as diet-induced obesity have been reported to be exacerbated in ApoE4-TR mice, suggesting that there are mechanistic differences in the glucose perturbations occurring in AD versus diabetes.

Acknowledgments

Acknowledgments: We thank technical assistance from Keri Crowder.

Footnotes

  • The authors declare no competing financial interests.

  • This work was supported by National Institutes of Health/National Institute on Aging Grants 1R01AG071782, 1R01AG062254, and 2P01AG012411.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

References

  1. ↵
    Abner EL, Nelson PT, Kryscio RJ, Schmitt FA, Fardo DW, Woltjer RL, Cairns NJ, Yu L, Dodge HH, Xiong C, Masaki K, Tyas SL, Bennett DA, Schneider JA, Arvanitakis Z (2016) Diabetes is associated with cerebrovascular but not Alzheimer’s disease neuropathology. Alzheimers Dement 12:882–889. https://doi.org/10.1016/j.jalz.2015.12.006 pmid:26812281
    OpenUrlCrossRefPubMed
  2. ↵
    Adams JN, Lockhart SN, Li L, Jagust WJ (2019) Relationships between tau and glucose metabolism reflect Alzheimer’s disease pathology in cognitively normal older adults. Cereb Cortex 29:1997–2009. https://doi.org/10.1093/cercor/bhy078 pmid:29912295
    OpenUrlPubMed
  3. ↵
    Alata W, Ye Y, St-Amour I, Vandal M, Calon F (2015) Human apolipoprotein E ɛ4 expression impairs cerebral vascularization and blood-brain barrier function in mice. J Cereb Blood Flow Metab 35:86–94. https://doi.org/10.1038/jcbfm.2014.172 pmid:25335802
    OpenUrlCrossRefPubMed
  4. ↵
    Arbones-Mainar JM, Johnson LA, Altenburg MK, Kim HS, Maeda N (2010) Impaired adipogenic response to thiazolidinediones in mice expressing human apolipoproteinE4. FASEB J 24:3809–3818. https://doi.org/10.1096/fj.10-159517 pmid:20501792
    OpenUrlCrossRefPubMed
  5. ↵
    Bachar-Wikstrom E, Wikstrom JD, Ariav Y, Tirosh B, Kaiser N, Cerasi E, Leibowitz G (2013) Stimulation of autophagy improves endoplasmic reticulum stress-induced diabetes. Diabetes 62:1227–1237.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Biernat J, Mandelkow EM, Schröter C, Lichtenberg-Kraag B, Steiner B, Berling B, Meyer H, Mercken M, Vandermeeren A, Goedert M, Mandelkow E (1992) The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J 11:1593–1597. https://doi.org/10.1002/j.1460-2075.1992.tb05204.x pmid:1563356
    OpenUrlPubMed
  7. ↵
    Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO (1996) Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up. Neurosci Lett 214:163–166. https://doi.org/10.1016/0304-3940(96)12905-0 pmid:8878109
    OpenUrlCrossRefPubMed
  8. ↵
    Botteri G, Salvadó L, Gumà A, Lee Hamilton D, Meakin PJ, Montagut G, Ashford MLJ, Ceperuelo-Mallafré V, Fernández-Veledo S, Vendrell J, Calderón-Dominguez M, Serra D, Herrero L, Pizarro J, Barroso E, Palomer X, Vázquez-Carrera M (2018) The BACE1 product sAPPβ induces ER stress and inflammation and impairs insulin signaling. Metabolism 85:59–75. https://doi.org/10.1016/j.metabol.2018.03.005 pmid:29526536
    OpenUrlPubMed
  9. ↵
    Cheng B, Mattson MP (1992) Glucose deprivation elicits neurofibrillary tangle-like antigenic changes in hippocampal neurons: prevention by NGF and bFGF. Exp Neurol 117:114–123. https://doi.org/10.1016/0014-4886(92)90120-f pmid:1323483
    OpenUrlCrossRefPubMed
  10. ↵
    Christensen A, Pike CJ (2019) APOE genotype affects metabolic and Alzheimer-related outcomes induced by Western diet in female EFAD mice. FASEB J 33:4054–4066. https://doi.org/10.1096/fj.201801756R pmid:30509127
    OpenUrlCrossRefPubMed
  11. ↵
    Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr. (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50:164–168. https://doi.org/10.1212/wnl.50.1.164 pmid:9443474
    OpenUrlCrossRefPubMed
  12. ↵
    de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, Tsui W, Kandil E, Scherer AJ, Roche A, Imossi A, Thorn E, Bobinski M, Caraos C, Lesbre P, Schlyer D, Poirier J, Reisberg B, Fowler J (2001) Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A 98:10966–10971. https://doi.org/10.1073/pnas.191044198 pmid:11526211
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Edlund AK, Chen K, Lee W, Protas H, Su Y, Reiman E, Caselli R, Nielsen HM (2021) Plasma apolipoprotein E3 and glucose levels are associated in APOE ɛ3/ɛ4 carriers. J Alzheimers Dis 81:339–354. https://doi.org/10.3233/JAD-210065 pmid:33814450
    OpenUrlPubMed
  14. ↵
    Fang W, Xiao N, Zeng G, Bi D, Dai X, Mi X, Ye Q, Chen X, Zhang J (2021) APOE4 genotype exacerbates the depression-like behavior of mice during aging through ATP decline. Transl Psychiatry 11:507. https://doi.org/10.1038/s41398-021-01631-0 pmid:34611141
    OpenUrlPubMed
  15. ↵
    Fleeman RM, Snyder AM, Kuhn MK, Chan DC, Smith GC, Crowley NA, Arnold AC, Proctor EA (2023) Predictive link between systemic metabolism and cytokine signatures in the brain of apolipoprotein E ε4 mice. Neurobiol Aging 123:154–169.
    OpenUrl
  16. ↵
    Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P (1998) High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55:937–945. https://doi.org/10.1001/archneur.55.7.937 pmid:9678311
    OpenUrlCrossRefPubMed
  17. ↵
    Groeneveld ON, Moneti C, Heinen R, de Bresser J, Kuijf HJ, Exalto LG, Boomsma JMF, Kappelle LJ, Barkhof F, Prins ND, Scheltens P, van der Flier WM, Biessels GJ; TRACE-VCI study group (2019) The clinical phenotype of vascular cognitive impairment in patients with type 2 diabetes mellitus. J Alzheimers Dis 68:311–322. https://doi.org/10.3233/JAD-180914 pmid:30775988
    OpenUrlPubMed
  18. ↵
    Hassing LB, Johansson B, Nilsson SE, Berg S, Pedersen NL, Gatz M, McClearn G (2002) Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer’s disease: a population-based study of the oldest old. Int Psychogeriatr 14:239–248. https://doi.org/10.1017/s104161020200844x pmid:12475085
    OpenUrlCrossRefPubMed
  19. ↵
    Heinonen O, Lehtovirta M, Soininen H, Helisalmi S, Mannermaa A, Sorvari H, Kosunen O, Paljärvi L, Ryynänen M, Riekkinen PJ Sr. (1995) Alzheimer pathology of patients carrying apolipoprotein E epsilon 4 allele. Neurobiol Aging 16:505–513. https://doi.org/10.1016/0197-4580(95)00076-q pmid:8544899
    OpenUrlCrossRefPubMed
  20. ↵
    Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC (2009) Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 6:31. https://doi.org/10.1186/1743-7075-6-31 pmid:19664276
    OpenUrlCrossRefPubMed
  21. ↵
    Hendrix RD, Ou Y, Davis JE, Odle AK, Groves TR, Allen AR, Childs GV, Barger SW (2021) Alzheimer amyloid-β-peptide disrupts membrane localization of glucose transporter 1 in astrocytes: implications for glucose levels in brain and blood. Neurobiol Aging 97:73–88. https://doi.org/10.1016/j.neurobiolaging.2020.10.001 pmid:33161213
    OpenUrlPubMed
  22. ↵
    Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T (1984) Alzheimer’s disease: a study of epidemiological aspects. Ann Neurol 15:335–341. https://doi.org/10.1002/ana.410150406 pmid:6742780
    OpenUrlCrossRefPubMed
  23. ↵
    Igel E, Haller A, Wolfkiel PR, Orr-Asman M, Jaeschke A, Hui DY (2021) Distinct pro-inflammatory properties of myeloid cell-derived apolipoprotein E2 and E4 in atherosclerosis promotion. J Biol Chem 297:101106. https://doi.org/10.1016/j.jbc.2021.101106 pmid:34425108
    OpenUrlPubMed
  24. ↵
    Jack CR Jr., Petersen RC, Xu Y, O’Brien PC, Smith GE, Ivnik RJ, Boeve BF, Tangalos EG, Kokmen E (2000) Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 55:484–489. https://doi.org/10.1212/wnl.55.4.484 pmid:10953178
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Jones NS, Watson KQ, Rebeck GW (2019) Metabolic disturbances of a high-fat diet are dependent on APOE genotype and sex. eNeuro 6:ENEURO.0267-19.2019. https://doi.org/10.1523/ENEURO.0267-19.2019
    OpenUrl
  26. ↵
    Jung HS, Chung KW, Won Kim J, Kim J, Komatsu M, Tanaka K, Nguyen YH, Kang TM, Yoon KH, Kim JW, Jeong YT, Han MS, Lee MK, Kim KW, Shin J, Lee MS (2008) Loss of autophagy diminishes pancreatic beta cell mass and function with resultant hyperglycemia. Cell Metab 8:318–324. https://doi.org/10.1016/j.cmet.2008.08.013 pmid:18840362
    OpenUrlCrossRefPubMed
  27. ↵
    Kloske CM, Wilcock DM (2020) The important interface between apolipoprotein E and neuroinflammation in Alzheimer’s disease. Front Immunol 11:754. https://doi.org/10.3389/fimmu.2020.00754 pmid:32425941
    OpenUrlCrossRefPubMed
  28. ↵
    Koren-Iton A, Salomon-Zimri S, Smolar A, Shavit-Stein E, Dori A, Chapman J, Michaelson DM (2020) Central and peripheral mechanisms in ApoE4-driven diabetic pathology. Int J Mol Sci 21:1289. https://doi.org/10.3390/ijms21041289
    OpenUrl
  29. ↵
    Kotredes KP, et al. (2021) Uncovering disease mechanisms in a novel mouse model expressing humanized APOEε4 and Trem2*R47H. Front Aging Neurosci 13:735524. https://doi.org/10.3389/fnagi.2021.735524 pmid:34707490
    OpenUrlCrossRefPubMed
  30. ↵
    Kulas JA, Franklin W, Smith NA, Manocha GD, Puig KL, Nagamoto-Combs K, Hendrix RD, Taglialatela G, Barger SW, Combs CK (2019) Ablation of amyloid precursor protein increases insulin degrading enzyme levels and activity in brain and peripheral tissues. Am J Physiol Endocrinol Metab 316:E106–E120. https://doi.org/10.1152/ajpendo.00279.2018 pmid:30422705
    OpenUrlPubMed
  31. ↵
    Lee CW, Shih YH, Wu SY, Yang T, Lin C, Kuo YM (2013) Hypoglycemia induces tau hyperphosphorylation. Curr Alzheimer Res 10:298–308. https://doi.org/10.2174/1567205011310030009 pmid:23036024
    OpenUrlPubMed
  32. ↵
    Lima D, Hacke ACM, Inaba J, Pessôa CA, Kerman K (2020) Electrochemical detection of specific interactions between apolipoprotein E isoforms and DNA sequences related to Alzheimer’s disease. Bioelectrochemistry 133:107447. https://doi.org/10.1016/j.bioelechem.2019.107447 pmid:32006858
    OpenUrlCrossRefPubMed
  33. ↵
    Liu Y, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX (2008) Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett 582:359–364. https://doi.org/10.1016/j.febslet.2007.12.035 pmid:18174027
    OpenUrlCrossRefPubMed
  34. ↵
    Martinon F, Burns K, Tschopp J (2002) The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10:417–426. https://doi.org/10.1016/s1097-2765(02)00599-3 pmid:12191486
    OpenUrlCrossRefPubMed
  35. ↵
    Mattar JM, Majchrzak M, Iannucci J, Bartman S, Robinson JK, Grammas P (2022) Sex differences in metabolic indices and chronic neuroinflammation in response to prolonged high-fat diet in ApoE4 knock-in mice. Int J Mol Sci 23:3921.
    OpenUrl
  36. ↵
    McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, DeLucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47:191–199. https://doi.org/10.1016/j.neuron.2005.06.030 pmid:16039562
    OpenUrlCrossRefPubMed
  37. ↵
    Meigs JB, Ordovas JM, Cupples LA, Singer DE, Nathan DM, Schaefer EJ, Wilson PW (2000) Apolipoprotein E isoform polymorphisms are not associated with insulin resistance: the Framingham Offspring Study. Diabetes Care 23:669–674. https://doi.org/10.2337/diacare.23.5.669 pmid:10834428
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Mosconi L, De Santi S, Li J, Tsui WH, Li Y, Boppana M, Laska E, Rusinek H, de Leon MJ (2008) Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging 29:676–692. https://doi.org/10.1016/j.neurobiolaging.2006.12.008 pmid:17222480
    OpenUrlCrossRefPubMed
  39. ↵
    Moser VA, Pike CJ (2017) Obesity accelerates Alzheimer-related pathology in APOE4 but not APOE3 mice. eNeuro 4:ENEURO.0077-17.2017. https://doi.org/10.1523/ENEURO.0077-17.2017
    OpenUrl
  40. ↵
    Needham BE, Wlodek ME, Ciccotosto GD, Fam BC, Masters CL, Proietto J, Andrikopoulos S, Cappai R (2008) Identification of the Alzheimer’s disease amyloid precursor protein (APP) and its homologue APLP2 as essential modulators of glucose and insulin homeostasis and growth. J Pathol 215:155–163. https://doi.org/10.1002/path.2343 pmid:18393365
    OpenUrlCrossRefPubMed
  41. ↵
    Ohm TG, Kirca M, Bohl J, Scharnagl H, Gross W, März W (1995) Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. Neuroscience 66:583–587. https://doi.org/10.1016/0306-4522(94)00596-w pmid:7644022
    OpenUrlCrossRefPubMed
  42. ↵
    Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, O’Neil JP, Janabi M, Lazaris A, Cantwell A, Vogel J, Santos M, Miller ZA, Bettcher BM, Vossel KA, Kramer JH, Gorno-Tempini ML, Miller BL, Jagust WJ, Rabinovici GD (2016) Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain 139:1551–1567. https://doi.org/10.1093/brain/aww027 pmid:26962052
    OpenUrlCrossRefPubMed
  43. ↵
    Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, Myers MG Jr., Ozcan U (2009) Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 9:35–51. https://doi.org/10.1016/j.cmet.2008.12.004 pmid:19117545
    OpenUrlCrossRefPubMed
  44. ↵
    Parcon PA, Balasubramaniam M, Ayyadevara S, Jones RA, Liu L, Shmookler Reis RJ, Barger SW, Mrak RE, Griffin WST (2018) Apolipoprotein E4 inhibits autophagy gene products through direct, specific binding to CLEAR motifs. Alzheimers Dement 14:230–242. https://doi.org/10.1016/j.jalz.2017.07.754 pmid:28945989
    OpenUrlCrossRefPubMed
  45. ↵
    Park S, Oh M, Kim JS, Lee JH, Yoon YW, Roh JH (2021) (18)F-THK-5351, fluorodeoxyglucose, and florbetaben PET images in atypical Alzheimer’s disease: a pictorial insight into disease pathophysiology. Brain Sci 11:465.
    OpenUrl
  46. ↵
    Peila R, Rodriguez BL, Launer LJ; Honolulu-Asia Aging Study (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 51:1256–1262. https://doi.org/10.2337/diabetes.51.4.1256 pmid:11916953
    OpenUrlAbstract/FREE Full Text
  47. ↵
    Pettersson US, Waldén TB, Carlsson PO, Jansson L, Phillipson M (2012) Female mice are protected against high-fat diet induced metabolic syndrome and increase the regulatory T cell population in adipose tissue. PLoS One 7:e46057. https://doi.org/10.1371/journal.pone.0046057 pmid:23049932
    OpenUrlCrossRefPubMed
  48. ↵
    Podolsky S, Leopold NA, Sax DS (1972) Increased frequency of diabetes mellitus in patients with Huntington’s chorea. Lancet 1:1356–1358. https://doi.org/10.1016/s0140-6736(72)91092-6 pmid:4113563
    OpenUrlCrossRefPubMed
  49. ↵
    Ragogna F, Lattuada G, Ruotolo G, Luzi L, Perseghin G (2012) Lack of association of apoE ε4 allele with insulin resistance. Acta Diabetol 49:25–32. https://doi.org/10.1007/s00592-011-0255-3 pmid:21290252
    OpenUrlPubMed
  50. ↵
    Raha S, Ghosh A, Dutta D, Patel DR, Pahan K (2021) Activation of PPARα enhances astroglial uptake and degradation of β-amyloid. Sci Signal 14:eabg4747. https://doi.org/10.1126/scisignal.abg4747 pmid:34699252
    OpenUrlPubMed
  51. ↵
    Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, Hyde K, Chapman D, Craft S (2004) Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 25:311–314. https://doi.org/10.1016/S0197-4580(03)00087-3 pmid:15123336
    OpenUrlCrossRefPubMed
  52. ↵
    Reger MA, Watson GS, Frey WH 2nd., Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27:451–458. https://doi.org/10.1016/j.neurobiolaging.2005.03.016 pmid:15964100
    OpenUrlCrossRefPubMed
  53. ↵
    Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D (1996) Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 334:752–758. https://doi.org/10.1056/NEJM199603213341202 pmid:8592548
    OpenUrlCrossRefPubMed
  54. ↵
    Reiman EM, Uecker A, Caselli RJ, Lewis S, Bandy D, de Leon MJ, De Santi S, Convit A, Osborne D, Weaver A, Thibodeau SN (1998) Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer’s disease. Ann Neurol 44:288–291. https://doi.org/10.1002/ana.410440226 pmid:9708558
    OpenUrlCrossRefPubMed
  55. ↵
    Riedel BC, Thompson PM, Brinton RD (2016) Age, APOE and sex: triad of risk of Alzheimer’s disease. J Steroid Biochem Mol Biol 160:134–147. https://doi.org/10.1016/j.jsbmb.2016.03.012 pmid:26969397
    OpenUrlCrossRefPubMed
  56. ↵
    Sadrolashrafi K, Craft S, Decourt B, Adem A, Wilson JR, Miller J, Sabbagh MN (2021) Is diabetes associated with increased pathological burden in Alzheimer’s disease? Alzheimers Dement (Amst) 13:e12248. https://doi.org/10.1002/dad2.12248 pmid:34796262
    OpenUrlPubMed
  57. ↵
    Seshadri S, Wolf PA, Beiser A, Au R, McNulty K, White R, D’Agostino RB (1997) Lifetime risk of dementia and Alzheimer’s disease. The impact of mortality on risk estimates in the Framingham Study. Neurology 49:1498–1504. https://doi.org/10.1212/wnl.49.6.1498 pmid:9409336
    OpenUrlAbstract/FREE Full Text
  58. ↵
    Shen T, Jiang J, Lu J, Wang M, Zuo C, Yu Z, Yan Z (2019) Predicting Alzheimer disease from mild cognitive impairment with a deep belief network based on 18F-FDG-PET images. Mol Imaging 18:1536012119877285. https://doi.org/10.1177/1536012119877285 pmid:31552787
    OpenUrlPubMed
  59. ↵
    Smailagic N, Lafortune L, Kelly S, Hyde C, Brayne C (2018) 18F-FDG PET for prediction of conversion to Alzheimer’s disease dementia in people with mild cognitive impairment: an updated systematic review of test accuracy. J Alzheimers Dis 64:1175–1194. https://doi.org/10.3233/JAD-171125 pmid:30010119
    OpenUrlCrossRefPubMed
  60. ↵
    Small GW, Mazziotta JC, Collins MT, Baxter LR, Phelps ME, Mandelkern MA, Kaplan A, La Rue A, Adamson CF, Chang L (1995) Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273:942–947. https://doi.org/10.1001/jama.1995.03520360056039
    OpenUrlCrossRefPubMed
  61. ↵
    Stuart CA, Ross IR, Howell ME, McCurry MP, Wood TG, Ceci JD, Kennel SJ, Wall J (2011) Brain glucose transporter (Glut3) haploinsufficiency does not impair mouse brain glucose uptake. Brain Res 1384:15–22. https://doi.org/10.1016/j.brainres.2011.02.014 pmid:21316350
    OpenUrlCrossRefPubMed
  62. ↵
    Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 272:17972–17980. https://doi.org/10.1074/jbc.272.29.17972 pmid:9218423
    OpenUrlAbstract/FREE Full Text
  63. ↵
    Sun X, Nie B, Zhao S, Ai L, Chen Q, Zhang T, Pan T, Wang L, Yin X, Zhang W, Shan B, Liu H, Liang S, Wang G (2020) Distinct relationships of amyloid-beta and tau deposition to cerebral glucose metabolic networks in Alzheimer’s disease. Neurosci Lett 717:134699. https://doi.org/10.1016/j.neulet.2019.134699 pmid:31874218
    OpenUrlPubMed
  64. ↵
    Tai LM, Thomas R, Marottoli FM, Koster KP, Kanekiyo T, Morris AW, Bu G (2016) The role of APOE in cerebrovascular dysfunction. Acta Neuropathol 131:709–723. https://doi.org/10.1007/s00401-016-1547-z pmid:26884068
    OpenUrlCrossRefPubMed
  65. ↵
    Tapiola T, Lehtovirta M, Ramberg J, Helisalmi S, Linnaranta K, Riekkinen P Sr., Soininen H (1998) CSF tau is related to apolipoprotein E genotype in early Alzheimer’s disease. Neurology 50:169–174. https://doi.org/10.1212/wnl.50.1.169 pmid:9443475
    OpenUrlAbstract/FREE Full Text
  66. ↵
    Thambisetty M, Jeffrey Metter E, Yang A, Dolan H, Marano C, Zonderman AB, Troncoso JC, Zhou Y, Wong DF, Ferrucci L, Egan J, Resnick SM, O’Brien RJ (2013) Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol 70:1167–1172. https://doi.org/10.1001/jamaneurol.2013.284 pmid:23897112
    OpenUrlCrossRefPubMed
  67. ↵
    Torosyan N, Sethanandha C, Grill JD, Dilley ML, Lee J, Cummings JL, Ossinalde C, Silverman DH (2018) Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer’s disease: results of a randomized, double-blinded, pilot study. Exp Gerontol 111:118–121. https://doi.org/10.1016/j.exger.2018.07.009 pmid:30006299
    OpenUrlPubMed
  68. ↵
    Tu Z, Keller MP, Zhang C, Rabaglia ME, Greenawalt DM, Yang X, Wang IM, Dai H, Bruss MD, Lum PY, Zhou YP, Kemp DM, Kendziorski C, Yandell BS, Attie AD, Schadt EE, Zhu J (2012) Integrative analysis of a cross-loci regulation network identifies App as a gene regulating insulin secretion from pancreatic islets. PLoS Genet 8:e1003107. https://doi.org/10.1371/journal.pgen.1003107 pmid:23236292
    OpenUrlCrossRefPubMed
  69. ↵
    Viitanen L, Pihlajamäki J, Miettinen R, Kärkkäinen P, Vauhkonen I, Halonen P, Kareinen A, Lehto S, Laakso M (2001) Apolipoprotein E gene promoter (-219G/T) polymorphism is associated with premature coronary heart disease. J Mol Med (Berl) 79:732–737. https://doi.org/10.1007/s001090100265 pmid:11862316
    OpenUrlCrossRefPubMed
  70. ↵
    Vitek MP, Brown CM, Colton CA (2009) APOE genotype-specific differences in the innate immune response. Neurobiol Aging 30:1350–1360. https://doi.org/10.1016/j.neurobiolaging.2007.11.014 pmid:18155324
    OpenUrlCrossRefPubMed
  71. ↵
    Weisgraber KH, Innerarity TL, Mahley RW (1982) Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 257:2518–2521. https://doi.org/10.1016/S0021-9258(18)34954-8
    OpenUrlFREE Full Text
  72. ↵
    Wu L, Zhang X, Zhao L (2018) Human ApoE isoforms differentially modulate brain glucose and ketone body metabolism: implications for Alzheimer’s disease risk reduction and early intervention. J Neurosci 38:6665–6681. https://doi.org/10.1523/JNEUROSCI.2262-17.2018 pmid:29967007
    OpenUrlAbstract/FREE Full Text
  73. ↵
    Zlokovic BV (2013) Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol 70:440–444. https://doi.org/10.1001/jamaneurol.2013.2152 pmid:23400708
    OpenUrlCrossRefPubMed
  74. ↵
    Zubenko GS, Stiffler S, Stabler S, Kopp U, Hughes HB, Cohen BM, Moossy J (1994) Association of the apolipoprotein E epsilon 4 allele with clinical subtypes of autopsy-confirmed Alzheimer’s disease. Am J Med Genet 54:199–205. https://doi.org/10.1002/ajmg.1320540306 pmid:7810577
    OpenUrlCrossRefPubMed

Synthesis

Reviewing Editor: Aniko Korosi, Universiteit van Amsterdam

Decisions are customarily a result of the Reviewing Editor and the peer reviewers coming together and discussing their recommendations until a consensus is reached. When revisions are invited, a fact-based synthesis statement explaining their decision and outlining what is needed to prepare a revision will be listed below. The following reviewer(s) agreed to reveal their identity: NONE. Note: If this manuscript was transferred from JNeurosci and a decision was made to accept the manuscript without peer review, a brief statement to this effect will instead be what is listed below.

This is a highly significant paper because it is the first time insulin signaling glucose tolerance has been evaluate in ApoE dependent. It is very well done and the discussion and results sections are very well written. There are no major concerns, but some minor concerns. The minor concerns include statistical presentation and figure presentation which are detailed below. Also the legends and the results section could be tweaked for it to be easier to interpret the findings, which make sense except require a reader slightly out of the field extra unnecessary time to make sense of it.

General Comments on Response to the review;

Strengths

• Improvement made in Response to Reviewer 1:

• Clarified issues like tau epitopes and sexes

• The authors added additional Abeta ELISA data and clarified basic question (Table 3, no changes were detected)

• Response to Reviewer 2

• Citations were added, but mostly the authors disagreed with reviewer 2, such as the problems with logic and quality of writing, but attempted to make minor accommodations to partially address Reviewer 2’s concerns, over the complexity that abeta effects on glucose are evident, but not E4 possible because both E4 and abeta impact glucose.

• Clarified issues like tau epitopes and sexes

o

• Novelty: This is the first time (surprisingly) that glucose regulation has been compared in ApoETR mice with and without Aꞵ accumulation. They also showed that glucose tolerance effects paralleled tau hyperphosphorylation and membrane translocation of astrocytic glucose transporter 1 in vitro.

Major Concerns

• None (See strengths above)

Minor Concerns and Comments

• Title :

o Suggest a slight modification to better identify the novelty; the main finding is glucose deregulation associated with E4 is sex dependent is not further enhanced by Abeta, while normal glucose regulation associated with E3 is deregulated by Abeta so for example a title like this seems more relevant. “Sex and baseline glucose degradation influence Abeta and ApoE effects on glucose deregulation"

• Methods:

were animals perfused.

•

• Reviewer Comments on graphs images were not clear; however the nature of the reviewers comments should not be a score driving issue; nevertheless below more detail on what should be changed in the graphs are made.

o Merging colors (light dark) to illustrate age or other variables for same genotype is not ideal; I suggest labeling the age or other variable on the x axis diagonally but using the same color for ApoE and always using one the colors hatched to indicate Abeta (for example ApoE3 always on color and ApoE4 always one color, but Abeta hatched and non Abeta solid.

o The legend for lines is difficult to read; I suggest slightly thicker line and use dotted or hatched lines for Abeta (analgous to above..

o Label additional information (age etc).

o Label the x axis Abeta consistently across figures graphs and Westerns. Sometimes Abeta is a row, and sometimes it is for example E3+abeta. Since some variables are added (age), it may be best to not hae Abeta as a row and have that variable as a row).

o The fonts images of the legend are often too small (e.g. for weeks). Try to make the fonts within figure as similar as possible

o

o

o Do not use the gray background in any graphs. Use white

•

Abstract

• The 1st three paragraphs are excessive introduction; please condense.

• Describe the McGowan model abeta model better the name of the line BRI-Aβ42 line and the citation, McGowan et al., 2005, and that it does not overexpress APP.

• The methods sentence(s) should add the n’s; and that astrocyte culture used af females;

• Results sentence should refer to lack of effect in females.

• Adding to overall conclusion and how it impacts the field (“this is the first time, that x,y,z”) and the lack of effect of females is surprising so I would add that (about models not mimicking menopause)

Introduction

• Last paragraph “we sought to should be a new paragraph. Delete the results; and explain the methods and variables in e.g. two sentences, and how that will answer needed questions.

Discussion

• Please revise first paragraph deleting the methods (except a preface phrase at beginning of sentences that describe results; just state the overall findings in this paragraph, and why it is important to the field. For example “despite the expectation that a,b,c would happened, because of d,e, and f, we surprisingly found that x,y, and z.”

• The sex discussion should be its own paragraph and comment on why there is a male effect at all.

• The rest of the discussion is clear and very well written.

• A short paragraph on limitations would strengthen paper eg not being able to model the sex effect.

• However, the conclusion could add a sentence of how it advance field, and what the next question is.

Figures and Legends and Statistics

• General:

o kDa’s should be shown in all images for all Westerns not just Figure 5).

o Visually the bars should be the same width if possible (fig 1,4). I suggest doing box plots or overlay data points over histogram, depending on requirements of eNEURO

o Data on females should be shown not just in figure 1; showing the negative data in females, seems extremely important to show visually as a graph, in the findings and edit legend accordingly (n=7-10, per group per sex. In which case the analysis should be two way ANOVA, and showing interaction with sex and F values of Factors (sex, transgene) I suggest adding the female as a different graph. The authors explained why these data weren’t shown; I suggest that it be shown, but it is optional; if not shown it should be repeated in Figure 2-3,5-6) that there were no impacts within females.

o The description in methods of post hoc should describe of post doc (e.g. Bonferroni or Tukey) & if there is no homogeneity of variance (required by ANOVA), if data was log transformed. It is not clear why different post-hocs were used for different graphs even within the same figure.

o One way ANOVA, seems the incorrect analysis; rather two way ANOVA, seems more appropriate. If there is a reason for one way it should be explained in methods. Otherwise, perform two way ANOVA, using factors like ApoE allele x Abeta status or x sex or x age. Please check with statistician.

o More meaningly titles should be used in text of legend. As written they are too general to appreciate main point.

Specific

Fig 1:

• Comment on legend text: need comma before which; p may need to be italicized depending on eNeuro requirements; spell out ITT and GTT (unless this is listed as an acceptable. acronym that does not require spelling out)

• Legend title, add “but not in females” or something indicating that result.

• Within the images there should be lines showing the comparisons because the comparisons for * are different , in one place asterisks is compared with E3 and the other the same single asterisk is comparison with E4. Fix Legend accordingly

• This should be two way ANOVA; it looks as if the Abeta factor is significant and the ApoE is not; and age factor non-significant; the F(df,df) = ? for these factors can be listed in legend.

• The age should not be a legend (black white) but a row in the x axis

• See above general regarding Lines.

Fig 2:

• Title: Change combines with synergizes

• The key point here is that within (fasting+ Abeta) there is an ApoE effect but no overall fasting. So since there is no effect of abeta or ApoE within non fasting, you can say that you analyzed within fasting (abeta x ApoE two way). Then say “no factors significant”. Then do a two way ANOVA for fasting (Abeta x tg) * report factors: F(df,df) =? Should be described for significant factors, which may include a Significant ApoE effect (if so report that F(df,df)=. And Factors not significant should say (ns).

• B and A should be flipped (see above)

• E4 with Abeta vs E3 is not a legitimate planned comparison and should be removed. Only put line between E4Abeta and E3Abeta.

• The y axes do not match;

• In text legend define “[Glc]b” Concentration of glucose in tail-vein blood ([Glc]b]. In image, use this nomenclature; it is used in legend but not in them image; I recommend that you not delete it form both since it is used throughout body of manuscript.

• The y axis labels should delete ‘fasted’ , ‘non fasted’ for simplicity. It is redundant to title in image (unnecessary).

Fig 3:

• Western blot image: none of the lanes are contiguous. I think it is important that some of the adjacent lanes be shown. The kDa should be listed, but they do not match likely due to the blot being curved (which is usually the case); understandably adjacent lanes are not shown because they were not loaded in that order. At least explain this in the legend (adjacent lanes are not shown because and bands to not line up because; alternatively and ideally, show adjacent lanes and label the treatment differently; for example E3 E4 E3 E4 E3/abeta E4 abeta; whatever the order.

• There is no line between ApoEs (without Abeta) but it looks as if E4 is generally impaired, so a two way ANOVA may show an ApoE effect and Abeta interaction. This could explain the interpretation better. Also is really hard to understand this figure showing plasmalemmal effect and interpretation due to the lack of explanation regarding the calculation in the text legend (and that cytosol effect was non significant?);

• Overall this is interpreted as a plasmalemmal effect but the western suggests more an organelle effect. It would be helpful to graph the organelle and cytosol separately. For example the organelle effect seems like no ApoE effect with Abeta, but E4 is higher than E3;

• Suggest deleting the word “cells” from title, since it suggest in vitro.

Fig 4:

• No Western shown for Glut1; if measure another way. Please state.

• Instead of “conspire’ I would use synergize which is more scientific, although conspire, may be okay for the body of the manuscript (but is unlikely to be acceptable to eNeuro in proofs

• The abbreviation used in the image needs to inserted into the text legend.

• The image should state “astrocytes in vitro “ or something indicating this is in vitro for ease of reading, else it blends with Figure 3 seeming redundant

• Y axis fonts are different; bar width is different (true for other figures, see general comments

• A main point of 4B, is that E4 has no problems with glucose uptake unmlesss there is Abeta; while many of the findings show pathology with E4 regardles of Abeta. This is a very important point that should be very clear in the discussion and abstract and subtitles.

• If 4B is normal glucose, put that in image (as it is already put in A). Also I suggest putting “uptake” in the image; because it is helpful and also clearer why that graph doesn’t have the low glucose group. ANOVA should be two way. It suggest and interaction between Abeta and ApoE with there be only an ApoE effect if E4 and Abeta. Since one key planned comparison should be E4+Abeta vs E3 +Abeta, especially that is the main point.

• The main point of GluT1 graphs (6A) is that

• In 4A, ApoE effect seem to goes opposite directions depending on glucose (although this may be misleading, since the significance is not shown, due to lack of homogeneity suggested by error bars, requiring a log transformation (that should be stated in the legend and the appropriate values for the log F(df,df) given or that it is ns). If it is ns, it is advisable to use the y axis log values so it doesn’t look like the low glucose effects go in opposite directions. If it is significant (response to glucose in E3, then draw the line). A two way ANOVA is likely to see a big ApoE vs glucose level interaction. Key planned comparisons E3 vs E3 low glucose vs E4 vs E4/ low glucose should be shown. This is extremely complex to interpret. A specific title should try to convey some detail. The main point for 4A is that in E3, Glut1 response to low glucose (but no line is shown to show significance) and E4 does not (or even goes in opposite direction)

• Interpretation of 4A derives a bit in part to B. so A and B should be flipped.

•

Fig. 5

• 5B: Two way ANOVA is needed; it looks like an ApoE effect, but no abeta effect and no interaction: State the that the latter F(df,df) values are non significant and the ApoE factor ( F*df,df)=?, p=?”; for proIL1, the key planned comparison is ApoE, so you should draw a parallel line over both E3s, and one over both E4s and connect, then should show one asterisk (p<0.05). The p<0.01 can be listed in the legend if necessary.

Fig. 6:

• State Age

• The main point of 6A.B is that with E4, you don’t need Abeta to show ‘pathology’; This makes a lot of sense, but is pretty hard for a reader to interpret at first glance, which is why the discussion and the subtitles should be made more clear.

• Font for 6A is too small, 6A,B are similar to Figure 1: Why isn’t 6A and 6B part of Figure 1. It is put here to compare with tau going similarly.

• 6C. suggests labeling AT8 instead pTau, then epitope and tau “total tau) you can state antibody name in legend

Back to top

In this issue

eneuro: 10 (4)
eNeuro
Vol. 10, Issue 4
April 2023
  • Table of Contents
  • Index by author
  • Masthead (PDF)
Email

Thank you for sharing this eNeuro article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Amyloid β-Peptide Effects on Glucose Regulation Are Dependent on Apolipoprotein E Genotype
(Your Name) has forwarded a page to you from eNeuro
(Your Name) thought you would be interested in this article in eNeuro.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Amyloid β-Peptide Effects on Glucose Regulation Are Dependent on Apolipoprotein E Genotype
Jin Hee Sung, Yang Ou, Steven W. Barger
eNeuro 26 April 2023, 10 (4) ENEURO.0376-22.2023; DOI: 10.1523/ENEURO.0376-22.2023

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Amyloid β-Peptide Effects on Glucose Regulation Are Dependent on Apolipoprotein E Genotype
Jin Hee Sung, Yang Ou, Steven W. Barger
eNeuro 26 April 2023, 10 (4) ENEURO.0376-22.2023; DOI: 10.1523/ENEURO.0376-22.2023
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Significance Statement
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
    • Synthesis
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • Alzheimer’s disease
  • amyloid β-peptide
  • apolipoprotein E
  • glucose
  • insulin
  • microtubule-associated protein Tau

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Research Article: Confirmation

  • Evidence That Dmrta2 Acts through Repression of Pax6 in Cortical Patterning and Identification of a Mutation Impairing DNA Recognition Associated with Microcephaly in Human
  • Nucleus Accumbens Dopamine Encodes the Trace Period during Appetitive Pavlovian Conditioning
  • Dissociating Frontal Lobe Lesion Induced Deficits in Rule Value Learning Using Reinforcement Learning Models and a WCST Analog
Show more Research Article: Confirmation

Disorders of the Nervous System

  • Release of Extracellular Matrix Components after Human Traumatic Brain Injury
  • Gene variants related to primary familial brain calcification: perspectives from bibliometrics and meta-analysis
Show more Disorders of the Nervous System

Subjects

  • Disorders of the Nervous System
  • Home
  • Alerts
  • Follow SFN on BlueSky
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Latest Articles
  • Issue Archive
  • Blog
  • Browse by Topic

Information

  • For Authors
  • For the Media

About

  • About the Journal
  • Editorial Board
  • Privacy Notice
  • Contact
  • Feedback
(eNeuro logo)
(SfN logo)

Copyright © 2025 by the Society for Neuroscience.
eNeuro eISSN: 2373-2822

The ideas and opinions expressed in eNeuro do not necessarily reflect those of SfN or the eNeuro Editorial Board. Publication of an advertisement or other product mention in eNeuro should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in eNeuro.